The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 06, 2024
Filed:
Apr. 23, 2021
Applicant:
Nxera Pharma Uk Limited, Cambridge, GB;
Inventors:
Miles Stuart Congreve, Cambridge, GB;
Stephen Philippe Andrews, Melbourn, GB;
Jonathan Stephen Mason, Cambridge, GB;
Christine Mary Richardson, Saffron Walden, GB;
Giles Albert Brown, Cambridge, GB;
Assignee:
Nxera Pharma UK Limited, Cambridge, GB;
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/506 (2006.01); A61K 31/4427 (2006.01); A61K 31/53 (2006.01); A61K 31/5355 (2006.01); A61K 31/5377 (2006.01); A61K 31/5386 (2006.01); C07D 253/07 (2006.01); C07D 401/04 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 403/04 (2006.01); C07D 403/12 (2006.01); C07D 405/04 (2006.01); C07D 405/10 (2006.01); C07D 413/04 (2006.01); C07D 413/14 (2006.01); C07D 417/04 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07D 487/04 (2006.01);
U.S. Cl.
CPC ...
C07D 401/04 (2013.01); A61K 31/4427 (2013.01); A61K 31/506 (2013.01); A61K 31/53 (2013.01); A61K 31/5355 (2013.01); A61K 31/5377 (2013.01); A61K 31/5386 (2013.01); C07D 253/07 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 405/04 (2013.01); C07D 405/10 (2013.01); C07D 413/04 (2013.01); C07D 413/14 (2013.01); C07D 417/04 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07D 487/04 (2013.01);
Abstract
According to the invention there is provided a compound of formula A1 which may be useful in the treatment of a condition or disorder ameliorated by the inhibition of the A-Aor, particularly, the Areceptor. A process for the preparation of the compound, pharmaceutical compositions comprising the compound, and methods of treatment comprising administration of an effective amount of the compound are also disclosed.